Novan Inc

NASDAQ:NOVN   9:37:29 AM EDT
4.39
-0.25 (-5.39%)
Products, Regulatory

Novan Announces Preclinical Data And Intent To Advance SB019 For Treatment Of COVID-19

Published: 11/09/2021 13:45 GMT
Novan Inc (NOVN) - Novan Announces Favorable Preclinical Safety Data and Intent to Advance Sb019 for Treatment of Covid-19.
Novan Inc - Pre-ind (investigational New Drug) Application Activities Are Underway With a Target of an Ind Submission No Later Than Q2 2022.
Novan Inc - Data Indicates Intranasal Administration of Sb019 Formulation Containing Berdazimer Sodium is Well-tolerated and Safe in Preclinical Study.